FOLD Financial Facts

Total operating expenses: 48.54M
Research and development: 18.28M
See Full Income Statement

Total current assets: 217.67M
Cash and cash equivalents: 63.66M
See Full Balance Sheet

Amicus Therapeutics, Inc. (FOLD) Earnings

  |   Expand Research on FOLD
Next EPS Date 11/9/16 *Est. EPS Growth Rate -48.1% *Last Qtr.
Average EPS % Beat Rate -33.4% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS -1.4% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/5/15 Q215 -$0.27-$0.24 -$0.03N/A$130K N/A Details
3/3/15 Q414 -$0.24-$0.18 -$0.06N/A$390K N/A Details
5/4/11 Q111 -$0.39-$0.35 -$0.04$6M$1.24M N/A Details
8/9/16 Q216 -$0.40-$0.33 -$0.07N/A$170K N/A Details
2/13/12 Q411 -$0.25-$0.37 +$0.12$922K$6.06M N/A Details
5/5/15 Q115 -$0.35-$0.21 -$0.14N/A$250K N/A Details
2/14/11 Q410 -$0.48-$0.15 -$0.33$922K$9M N/A Details
11/5/12 Q312 -$0.31-$0.24 -$0.07$5.8M$8.82M N/A Details